RecruitingNCT06280313

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhiyong Huang
Principal Investigator
Zhiyong Huang
Tongji Hospital
Intervention
Splenectomy+Targeted therapy+ Immunotherapy(combination_product)
Enrollment
60 target
Eligibility
18-75 years · All sexes
Timeline
20242028

Study locations (1)

Collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Zhongnan Hospital · Renmin Hospital of Wuhan University · Taihe Hospital · Hubei Cancer Hospital · Xiangyang Central Hospital · Wuhan Central Hospital · Yichang Third Renmin Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06280313 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials